Form D · Pharmaceuticals
TherapeuticsMD, Inc.
Boca Raton, FL · CIK 0000025743
Offering snapshot reported Jul 11, 2023 · SEC filing
- Reported sold
- $1.15M Offering amount: $5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 29, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 11, 2023 | Initial | $1,149,998 | No comparison | 2 | SEC filing |
| Nov 14, 2022 | Initial | $7,000,000 | No comparison | 6 | SEC filing |
| Oct 17, 2022 | Initial | $7,000,000 | No comparison | 6 | SEC filing |
| Aug 16, 2022 | Initial | $15,000,000 | No comparison | 6 | SEC filing |
| Aug 14, 2020 | Initial | $7,500,000 | No comparison | 3 | SEC filing |
| Oct 10, 2012 | Initial | $8,500,001 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-486406
Pursuant to a Subscription Agreement with Rubric Capital Management LP, the Company may sell, at the Company's election, up to an aggregate of 5,000,000 shares of the Company's common stock, at an aggregate purchase price of up to $5,000,000.
Source: Form D, filed Jul 11, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Bernick | Executive |
| Brian Bernick, M.D. | Director, Executive |
| Paul Bisaro | Director |
| Edward Borkowski | Executive |
| J. Martin Carroll | Director |
| Daniel A. Cartwright | Executive |
| Cooper C. Collins | Director |
| James C. D'arecca | Executive |
| Michael C. Donegan | Executive |
| Robert G. Finizio | Director, Executive |
| Mark Glickman | Executive |
| Samuel A. Greco | Director |
| Mitchell L. Krassan | Executive |
| Robert V. La Penta, Jr. | Director |
| Karen Ling | Director |
| John C.K. Milligan Iv | Director, Executive |
| John C.K. Milligan, Iv | Executive |
| Jules A. Musing | Director |
| Gail Naughton | Director |
| Hugh O'dowd | Director, Executive |
| Justin Roberts | Director |
| Angus C. Russell | Director |
| Nicholas Segal | Director |
| Tommy G. Thompson | Director |
| Marlan Walker | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
951 Yamato Road, Suite 220
Boca Raton, FL, 33431
Boca Raton, FL, 33431